These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 12166035)
1. Novel approaches to anemia associated with cancer and chemotherapy. Kolesar JM Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Patton J; Reeves T; Wallace J Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098 [TBL] [Abstract][Full Text] [Related]
4. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304 [TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Cersosimo RJ; Jacobson DR Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942 [TBL] [Abstract][Full Text] [Related]
6. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629 [TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa: potential role in managing anemia in cancer patients. Pirker R; Smith R Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980 [TBL] [Abstract][Full Text] [Related]
8. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Case AS; Rocconi RP; Kilgore LC; Barnes MN Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa. Thames WA; Smith SL; Scheifele AC; Yao B; Giffin SA; Alley JL Pharmacotherapy; 2004 Mar; 24(3):313-23. PubMed ID: 15040644 [TBL] [Abstract][Full Text] [Related]
12. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Wilhelm-Leen ER; Winkelmayer WC Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816 [TBL] [Abstract][Full Text] [Related]
13. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507 [TBL] [Abstract][Full Text] [Related]
14. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Scott SD Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166 [TBL] [Abstract][Full Text] [Related]
16. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544 [TBL] [Abstract][Full Text] [Related]
17. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997 [TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568 [TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Hudson JQ; Sameri RM Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584 [TBL] [Abstract][Full Text] [Related]
20. Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia. Bloomfield M; Jaresko G; Zarek J; Dozier N Pharmacotherapy; 2003 Dec; 23(12 Pt 2):110S-118S. PubMed ID: 14695000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]